MYGN Financial Facts

Cost of molecular diagnostic testing: 32.8M
Total costs and expenses: 142.92M
See Full Income Statement

Total liabilities and stockholders' equity: 809.01M
Total current liabilities: 67.73M
See Full Balance Sheet

Myriad Genetics Inc. (MYGN) Earnings

  |   Expand Research on MYGN
Next EPS Date 2/4/15 *Est. EPS Growth Rate -63.2% *Last Qtr.
Average EPS % Beat Rate +8.2% Revenue Growth Rate -16.6% *Last Qtr.
Average % Move 1-Wk after EPS -3.7% Normal Earnings Time After Close
Date  Qtr EPS Cons. Surprise Revs Cons. Gd. 1-Week % 1-Day % Details
11/4/14 Q115 $0.25$0.32 -$0.07$168.8M$175M Details
8/12/14 Q414 $0.48$0.46 +$0.02$188.8M$187.68M Details
5/6/14 Q314 $0.48$0.45 +$0.03$176.2M$175.23M = Details
2/4/14 Q214 $0.66$0.46 +$0.20$204.06M$176.02M = Details
11/5/13 Q114 $0.68$0.46 +$0.22$202.47M$167.64M = Details
8/13/13 Q413 $0.53$0.44 +$0.09$174.1M$159.87M = Details
2/5/13 Q213 $0.42$0.38 +$0.04$149.1M$143.71M Details
11/5/12 Q113 $0.36$0.32 +$0.04$133.44M$129.43M Details